There are no reports of QTc prolongation with bevacizumab in clinical trials [26], and a study of 87 cancer patients treated with aflibercept, which has a higher affinity for binding VEGF, showed a mean increase in the QTc interval of only 8.4 ms [42]. This evidence concerns the gene VEGFA and cancer.